
Wanted: Independent directors for PSU boards. But where is the approval?
Mumbai: Over three-fourths of India's listed public sector enterprises do not have the requisite number of independent directors, as these companies continue to wait for clearance from various government departments.
As many as 62 out of 79 listed PSUs lack the mandated number of independent directors, according to data from Prime Database. Despite repeated regulatory reminders, these companies await clearances from their respective ministries, delaying crucial appointments and inviting penalties from stock exchanges.
Government-owned firms, including Hindustan Aeronautics Ltd, Indian Oil Corp. Ltd, Indian Railway Catering and Tourism Corp, State Bank of India, National Aluminium Company Ltd. and Steel Authority of India Ltd, did not have the minimum number of independent directors as of 2 June, according to Prime Database, a Mumbai-based market data tracking firm.
The list of non-compliant PSUs includes banks, oil and gas companies, metals and mining firms, power utilities, telecommunications, railways, and engineering firms.
According to the Securities and Exchange Board of India's listing regulations, at least one-third of a listed entity's board members must comprise independent directors. Additionally, if the chairman is an executive director, at least half of the board must consist of independent directors.
Also Read: HPCL gets new chief, four more large PSUs in queue
Boardroom bottlenecks
There are more red flags when it comes to board committees: 64 PSUs lack an independent director as chairperson of their audit committee, and 68 companies do not have independent chairs for their nomination and remuneration panels.
Additionally, 14 of the listed PSUs are yet to appoint a single woman director, despite gender diversity requirements, according to Prime Database.
'It's ironic that we are asking all private sector companies to comply with these requirements when government-owned companies themselves are non-compliant," said Pranav Haldea, managing director at Prime Database.
With PSUs failing to comply with the market regulator's rules, many have been fined by stock exchanges.
Last week, National Aluminium Company Ltd (Nalco) was fined ₹33.32 lakh for having only three independent directors—two short of the required five—on its 10-member board.
A spokesperson for Nalco said the company was continuously following up with the ministry of mines, its administrative ministry, for the appointment of the requisite number of independent directors.
The bottleneck lies in the approval process across various ministries, according to proxy advisory firms. 'The Prime Minister's Office should send a strong message to all concerned ministries and PSU companies that they need to be compliant, as non-compliance by PSUs doesn't send the right message to investors," said Shriram Subramanian, founder and managing director of InGovern Research Services, a proxy advisory firm.
'For instance, when the government, as a major shareholder, is involved in abusive transactions or there is trouble with key management, independent directors are the custodians of minority shareholders' interests," Subramanian said.
Also Read: India's PSU banks outshine private peers in arresting bad loans
Many of the largest money managers, including BlackRock and Vanguard, have voiced their concerns when these companies have sought shareholder approval for the appointment of directors, according to voting disclosures reviewed by Mint.
In August last year, Hindustan Aeronautics sought shareholder approval for the appointment of former chairman C.B. Ananthakrishnan. Nearly a fourth of public institutions opposed the decision.
'Nominee serves as chair of the board and bears responsibility for lack of independence. Nominee is an executive director on the audit committee," noted BlackRock, the world's largest money manager, with $11.6 trillion in assets under management.
In the same month, Hindustan Petroleum Corp. sought shareholders' approval for the appointment of Pankaj Kumar as a director, but 28.35% of public institutions, including Vanguard, opposed his re-appointment.
Despite governance lapses, investor interest in PSUs has surged. The BSE PSU Index, which comprises 63 companies, has outperformed the Sensex over the last five years. The index has gained 301% between 5 June 2020 and 3 June 2025, while the Sensex has risen by 135.5% during this period.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New Indian Express
17 minutes ago
- New Indian Express
Ample Parks launches industrial and logistics park at Mahindra World City
CHENNAI: Ample Parks, a joint venture between UK-based private equity firm Actis and Mahindra Lifespaces, has launched a 71-acre industrial and logistics park within the Domestic Tariff Area (DTA) of Mahindra World City (MWC), marking its foray into industrial real estate market. Backed by a planned investment of Rs 800 crore, the facility is the largest Grade-A industrial space within MWC's DTA and one of the few large-format developments of its kind in the region. The company plans to expand its land portfolio tenfold over the next five to seven years to build a pan-India platform. Located along the Oragadam-Maraimalai Nagar corridor, the park is designed to cater to industries including automotive, engineering, electronics and white goods. It offers 2.1 million sq ft of leasable area with both ready-to-move-in and built-to-suit options. Once fully operational, the park is expected to generate Rs 110 crore in annual revenue and over Rs 1,400 crore in a decade. It is also projected to create nearly 11,000 direct and indirect jobs. 'Ample Parks MWC is a future-ready ecosystem that integrates industrial, commercial, and logistics capabilities,' said Akash Rastogi, CEO and Director of Ample Parks. 'This is just the beginning, we intend to replicate this model across India's high-growth corridors.'


Time of India
32 minutes ago
- Time of India
Global goods trade gains as tariff fears speed imports, WTO says
Tired of too many ads? Remove Ads Global merchandise trade accelerated in the World Trade Organization's latest assessment, with a surge in imports tied to tariff stockpiling outweighing a slowdown in export WTO 's goods barometer rose to 103.5 in the first quarter, the highest level since August 2021, from the previous reading of 102.8, released in March, the Geneva-based organization said Thursday. The baseline of 100 indicates growth over the next quarter that's in line with medium-term orders were the only category in negative territory, the data showed. Increases were seen in air freight and container shipping along with rising demand for autos and electronics, the WTO President Donald Trump's higher taxes on goods entering the US — and threats to raise them even higher — have led companies to rush orders to avoid the extra costs.'This indicates strong trade volume growth in the first several months of 2025 possibly due to importers moving up purchases of goods in anticipation of higher tariffs in the future,' the report said. 'If so, trade growth should slow later in the year as sellers draw down inventories rather than importing more goods.'
&w=3840&q=100)

Business Standard
40 minutes ago
- Business Standard
Torrent Pharma share pops 4% on ₹25,689-cr JB Chem deal; analysts cautious
Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore. Tanmay Tiwary New Delhi Torrent Pharma share price today: Pharmaceutical company Torrent Pharmaceuticals shares were in focus on Monday, June 30, after the company announced a massive ₹25,689-crore deal to acquire JB Chemicals & Pharmaceuticals (JBCP). The Torrent Pharmaceuticals share surged as much as 3.89 per cent intraday to ₹3,474.60 apiece before paring gains. At last count, shares were trading 0.72 per cent higher at ₹3,368.35, even as the BSE Sensex remained flat around 84,003.81. The deal Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore. The transaction, structured in two phases, begins with Torrent Pharmaceuticals acquiring 46.39 per cent stake via a share purchase agreement (SPA) at ₹1,600 per share, amounting to ₹11,917 crore. This will be followed by an open offer to buy up to 26 per cent from public shareholders at ₹1,639 per share. Additionally, Torrent Pharmaceuticals said that it aims to acquire 2.8 per cent of JB Chemicals and Pharmaceuticals' equity from certain employees at the same price offered to KKR. As part of the transaction, Torrent Pharmaceuticals and JB Chemicals and Pharmaceuticals will merge—JB Chemicals shareholders will receive 51 Torrent Pharmaceuticals' shares for every 100 JB Chemicals and Pharmaceuticals shares held. The deal is now pending shareholder and Competition COmmission of India (CCI) approvals and is expected to close in six months. Brokerages' view Brokerages broadly see the deal as strategically major, though the near-term impact remains mixed. According to domestic brokerage firm Motilal Oswal, the acquisition provides Torrent Pharmaceuticals with a diversified branded portfolio that includes several potential mega brands, a pan-India reach supported by a 2,800-strong medical representative field force, robust manufacturing infrastructure for multiple dosage forms, and access to a growing Contract Development and Manufacturing Organisation (CDMO) business driven by lozenges. The brokerage believes this acquisition is value accretive over the medium to long-term. Excluding the impact of JB Chemicals and Pharmaceuticals, Torrent Pharmaceuticals is expected to post a 12 per cent revenue, 14 per cent Ebitda, and 23 per cent PAT CAGR over FY25–27. The brokerage values the stock at 38x 12-month forward earnings, arriving at a target price of ₹3,430. However, it maintained a 'Neutral' rating, citing limited upside from current levels despite the deal's long-term merits. Those at Japan-based foreign brokerage firm Nomura noted that the move aligns with Torrent Pharmaceuticals' history of inorganic growth, particularly in India. The acquisition offers near-term cost synergies and potential long-term revenue synergies, especially as both firms have a dominant presence in the Cardiac and Gastro segments. However, it flagged concerns around execution risks given the unprecedented size of this deal for Torrent. Unlike past acquisitions, valuation premiums are higher, and there's limited headroom for operational improvement as JBCP is already a well-run business with strong market share in key products. In the near-term, the acquisition could be earnings dilutive, especially when factoring in higher interest and amortisation costs. Excluding amortisation, the deal may be marginally EPS accretive—if merged using Torrent stock. Thus, Nomura maintained a 'Neutral' rating on Torrent Pharmaceuticals with a target price of ₹3,580, based on 25x FY27 Ebitda of ₹4,850 crore. The stock currently trades at 26.1x one-year forward Ebitda. While analysts are mixed on the immediate financial impact, the Street appears optimistic about Torrent Pharmaceuticals' long-term strategic play in scaling up its domestic and international presence through this acquisition.